<DOC>
	<DOC>NCT02143622</DOC>
	<brief_summary>To establish whether LJM716 in combination with cetuximab is safe and has beneficial effects in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma.</brief_summary>
	<brief_title>Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Most recent regimen contains both platinum and cetuximab (Phase II, group B). ECOG Performance Status (PS) ≤ 2. Recovery from all AEs of previous anticancer therapies, to baseline or to CTCAE Grade ≤ 1, except for alopecia. Measurable disease as determined by RECIST v1.1. Previous antiHER3 antibody treatment. Symptomatic brain metastasis. Prior systemic anticancer treatment, within a period of time that is shorter than the cycle length used for that treatment prior to starting study treatment. Prior anaphylactic or other severe infusion reaction to human immunoglobulin or antibody formulations. Inadequate end organ function. Ongoing diarrhea CTCAE Grade ≥ 2. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Head and neck cancer</keyword>
</DOC>